Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) Operating Margin (2017 - 2025)

Historic Operating Margin for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to 546.15%.

  • Arcus Biosciences' Operating Margin fell 3274000.0% to 546.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 156.25%, marking a year-over-year decrease of 353400.0%. This contributed to the annual value of 127.91% for FY2024, which is 1626900.0% up from last year.
  • As of Q3 2025, Arcus Biosciences' Operating Margin stood at 546.15%, which was down 3274000.0% from 5.0% recorded in Q2 2025.
  • Over the past 5 years, Arcus Biosciences' Operating Margin peaked at 79.25% during Q4 2021, and registered a low of 825.87% during Q3 2021.
  • Moreover, its 5-year median value for Operating Margin was 286.21% (2023), whereas its average is 338.75%.
  • Over the last 5 years, Arcus Biosciences' Operating Margin had its largest YoY gain of 17881200bps in 2021, and its largest YoY loss of -8282800bps in 2021.
  • Quarter analysis of 5 years shows Arcus Biosciences' Operating Margin stood at 79.25% in 2021, then plummeted by -375bps to 217.65% in 2022, then plummeted by -35bps to 293.55% in 2023, then crashed by -35bps to 396.15% in 2024, then tumbled by -38bps to 546.15% in 2025.
  • Its last three reported values are 546.15% in Q3 2025, 5.0% for Q2 2025, and 435.71% during Q1 2025.